secwatch.observer — SEC 8-K summary
======================================

Issuer:     GALECTIN THERAPEUTICS INC (GALT)
CIK:        0001133416
Form:       8-K
Filed at:   2026-05-15T11:50:30+00:00
Accession:  0001140361-26-021496
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Galectin Q1 net loss narrows to $5.1M; belapectin data at EASL, FDA meeting ahead
--------------------------------------------------------------------------------

- Net loss of $5.1M ($0.08 per share) vs $9.6M ($0.15) in Q1 2025; R&D expense fell to $2.2M from $6.5M.
- Cash $14.1M as of Mar 31, plus $10M credit line from chairman; company expects to fund ops through May 2027.
- Belapectin 2 mg/kg showed statistically significant liver stiffness reductions (FibroScan) at Weeks 26, 52, 78 in NAVIGATE trial.
- Oral/poster presentations at EASL Congress May 28-30; Type-C FDA meeting scheduled for Q2 2026.
- Board appointed Dr. Henry Brem in Jan 2026; KOL event on MASH cirrhosis held in March 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133416/000114036126021496/0001140361-26-021496-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133416/000114036126021496/ef20073003_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-021496

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer